share_log

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A: Others

Transcode Therapeutics | DEFA14A：其他
美股SEC公告 ·  2024/06/08 04:03

Moomoo AI 已提取核心訊息

Transcode Therapeutics, Inc. has filed an amendment to its definitive proxy statement with the SEC to correct an error regarding the quorum requirement for its upcoming Annual Meeting of Stockholders. The amendment clarifies that a quorum will require one-third of the outstanding shares entitled to vote, either present in person or represented by proxy. This correction aligns with the company's Amended and Restated Bylaws and the Delaware General Corporation Law. The Annual Meeting is scheduled for June 13, 2024, at Goodwin Procter LLP's offices in Boston, MA. The amendment does not change any other information in the original proxy statement, and stockholders who have already submitted their proxy cards or voting instructions do not need to take further action unless they decide to change their vote.
Transcode Therapeutics, Inc. has filed an amendment to its definitive proxy statement with the SEC to correct an error regarding the quorum requirement for its upcoming Annual Meeting of Stockholders. The amendment clarifies that a quorum will require one-third of the outstanding shares entitled to vote, either present in person or represented by proxy. This correction aligns with the company's Amended and Restated Bylaws and the Delaware General Corporation Law. The Annual Meeting is scheduled for June 13, 2024, at Goodwin Procter LLP's offices in Boston, MA. The amendment does not change any other information in the original proxy statement, and stockholders who have already submitted their proxy cards or voting instructions do not need to take further action unless they decide to change their vote.
Transcode Therapeutics, Inc.已向美國證券交易委員會提交了一份修正它即將召開的股東年會的確定性代理聲明的修正案，並更正了關於法定人數的錯誤要求。修正案澄清了法定人數將要求出席人數或代理代表的持有表決權的流通股份三分之一以上。這一更正符合公司修正後的章程和特拉華州公司法。年度股東大會定於2024年6月13日在Goodwin Procter LLP的波士頓辦事處舉行。修正案不會更改原代理聲明中的任何其他信息，已經提交代理卡或投票指示的股東除非決定更改票，否則無需採取進一步行動。
Transcode Therapeutics, Inc.已向美國證券交易委員會提交了一份修正它即將召開的股東年會的確定性代理聲明的修正案，並更正了關於法定人數的錯誤要求。修正案澄清了法定人數將要求出席人數或代理代表的持有表決權的流通股份三分之一以上。這一更正符合公司修正後的章程和特拉華州公司法。年度股東大會定於2024年6月13日在Goodwin Procter LLP的波士頓辦事處舉行。修正案不會更改原代理聲明中的任何其他信息，已經提交代理卡或投票指示的股東除非決定更改票，否則無需採取進一步行動。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    特斯拉績後巨震，後市你怎麽看？
    特斯拉2024年Q4營收257.1億美元，同比增長2%，不及預期。Cybercab計劃2026年投產，預計車輛業務將於2025年恢復增長。面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？
    TSLA收益預覽：猜測開盤價贏取獎勵！